CDC says benefits of J&J Covid vaccine still outweigh risks after reports of rare neurological disorder
Vials of Johnson & Johnson’s Janssen coronavirus disease (COVID-19) vaccine.
Johnson & Johnson via Reuters
There have been 100 reported cases of a rare, but serious, neurological disorder following Johnson & Johnson Covid-19 vaccination, but preliminary data suggests the benefits of the shots still outweigh the risks, the Centers for Disease Control and Prevention said Thursday.
There have been 8.1 cases of Guillain-Barre syndrome per 1 million doses, which is higher than expected in the general population and close to eight times the rate seen in Pfizer and Moderna’s shots, according to slides published Thursday ahead of a presentation before the CDC’s Advisory Committee on Immunization Practices. Guillain-Barre is a rare neurological disorder in which the body’s immune system mistakenly attacks part of the nervous system.
The data doesn’t show a similar pattern with Pfizer’s or Moderna’s vaccine, the U.S. agency said. By comparison, there has been roughly 1 case of Guillain-Barre per million doses for people who received either of the two-dose mRNA vaccines, according to the agency.
The additional data comes a little over a week after the Food and Drug Administration announced a new warning for the J&J shot after preliminary reports of Guillain-Barre syndrome were detected in some J&J recipients.
The new warning was just the latest setback for J&J, which has suffered from production problems of its vaccine as well as public concerns about a rare, potentially life-threatening, blood clotting disorder linked to its shots.
Out of the 100 reported cases of Guillain-Barre syndrome, 95 people were seriously ill, according to the CDC. One person – a 57-year-old man with preexisting conditions – died. The reported cases largely occurred about two weeks after vaccination and mostly in males, with a median age of 57, according to the data. More than 12 million of the J&J shots have been administered in the U.S., according to the CDC.